<DOC>
	<DOCNO>NCT02790996</DOCNO>
	<brief_summary>The study aim compare efficacy , safety pharmacokinetics ( PK ) optimise dose standard dose regimen vancomycin neonates infant age ≤ 90 day late onset bacterial sepsis know suspect caused Gram-positive microorganism</brief_summary>
	<brief_title>Neonatal Vancomycin Trial</brief_title>
	<detailed_description>Detailed objective study : - To compare efficacy optimised vancomycin dose regimen standard vancomycin dose regimen patient late onset , bacterial sepsis , know suspect caused Gram-positive microorganism . - To compare safety vancomycin ( include renal hearing safety ) allocation group intention treat ( ITT ) population - To describe PK parameter accord vancomycin dose regimen outcome use population PK model ITT population - To describe PK/PD term probability target attainment ( PTA ) different vancomycin dose regimen ITT per protocol ( PP ) population - To describe outcome duration therapy end vancomycin treatment short term follow-up visit allocation group ITT PP population - To compare clinical outcome antibacterial susceptibility infect organism - To compare colonisation resistant microorganism ( e.g . vancomycin-resistant enterococci ( VRE ) ) Candida spp . allocation group baseline , TOC short-term follow-up - To validate across multiple centre host biomarker panel allow improve diagnosis bacterial sepsis monitor response antibacterial therapy</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Postnatal age ≤ 90 day AND Postnatal age ≥ 72 hour onset sepsis AND Clinical sepsis define presence three clinical laboratory criterion list OR Confirmed , significant bacterial sepsis define positive culture Grampositive bacterium normally sterile site least one clinical one laboratory criterion list , 24 hour randomisation Clinical criterion hyper hypothermia , hypotension impair peripheral perfusion mottle skin , apnoea increase oxygen requirement increase requirement ventilatory support , bradycardic episode tachycardia , worsen feed intolerance abdominal distension , lethargy hypotonia irritability Laboratory criterion : white blood cell ( WBC ) count &lt; 4 &gt; 20 x 109 cells/L immature total neutrophil ratio ( I/T ) &gt; 0.2 platelet count &lt; 100 x 109/L Creactive protein ( CRP ) &gt; 10 mg/L glucose intolerance define blood glucose value &gt; 180 mg/dL ( &gt; 10 mmol/L ) receive normal glucose amount ( 8 15 g/kg/day ) metabolic acidosis define base excess ( BE ) &lt; 10 mmol/L ( 10 mEq/L ) blood lactate value &gt; 2 mmol/L Administration systemic antibiotic regimen 24 hour prior randomisation , unless change drive apparent lack efficacy original regimen Treatment vancomycin ≥ 24 hour time within 7 day enrolment Known toxicity , hypersensitivity intolerance vancomycin Known renal impairment urinary output &lt; 0.7 ml/kg/hour 24 hour creatinine value ≥ 100 µmol/L ( 1.13 mg/dL ) Patient receiving ( plan receive ) haemofiltration , haemodialysis , peritoneal dialysis , extracorporeal membrane oxygenation ( ECMO ) cardiopulmonary bypass Severe congenital malformation infant expect survive 3 month Patient know S. aureus ( MSSA MRSA ) bacteraemia Patient osteomyelitis , septic arthritis , urinary tract infection ( UTI ) meningitis Patient high suspicion of/confirmed sepsis cause Gramnegative organism fungi Other situation treat physician considers different empiric antibiotic regimen necessary Current participation clinical study investigational medicinal product ( IMP ) Postrandomisation exclusion • Any participant find Gramnegative fungal sepsis , osteomyelitis , septic arthritis , UTI , meningitis S. aureus ( MSSA MRSA ) bacteraemia randomisation exclude analysis . Participants receive least one dose study vancomycin follow safety</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>sepsis</keyword>
	<keyword>neonate</keyword>
	<keyword>vancomycin</keyword>
</DOC>